Evidence map›Paper›PMID 41524932›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026

Clinicopathological characteristics, incidence trends, and prognostic factors of salivary gland secretory carcinoma: a SEER database analysis (2011-2021).

Yu-Dan Cao, Hong-Wei Sun, Cheng-Peng Zha, Zai-Hui Wang, Chuan-Zheng Sun

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Comment on "Clinicopathological characteristics, incidence trends, and prognostic factors of salivary gland secretory carcinoma: a SEER database analysis (2011-2021)".European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Yu-Dan CaoHealth Science Center, Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, China.
Hong-Wei SunHealth Science Center, Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, China.
Cheng-Peng ZhaDepartment of Head Neck and Thyroid Surgery Section II, the Yunnan Cancer Hospital, Third Affiliated Hospital of Kunming Medical University, 519 Kunzhou Road, Kunming, 650118, Yunnan, China.
Zai-Hui WangDepartment of Head Neck and Thyroid Surgery Section II, the Yunnan Cancer Hospital, Third Affiliated Hospital of Kunming Medical University, 519 Kunzhou Road, Kunming, 650118, Yunnan, China.
Chuan-Zheng SunDepartment of Head Neck and Thyroid Surgery Section II, the Yunnan Cancer Hospital, Third Affiliated Hospital of Kunming Medical University, 519 Kunzhou Road, Kunming, 650118, Yunnan, China. scz007@126.com.ORCID http://orcid.org/0000-0003-2893-8335

Funding

National Natural Science Foundation of China 82060499National Natural Science Foundation of China 82360568
6 · The paper itself

Abstract

purposeThis study aimed to comprehensively analyze salivary gland secretory carcinoma (SGSC) using a large population-based cohort to determine temporal patterns, identify independent survival predictors, and evaluate treatment effectiveness for optimizing clinical management.

methodsWe conducted a retrospective cohort study using data from the Surveillance, Epidemiology, and End Results (SEER) database. A total of 212 patients diagnosed with SGSC between 2011 and 2021 were included. We analyzed clinicopathological features, incidence trends, and prognostic factors using Kaplan-Meier analysis and Cox proportional hazards models.

resultsWith a median follow-up duration of 36.5 months, the overall 5-year and 10-year survival rates were 89.93% and 86.53%, respectively. The incidence of SGSC has shown a significant upward trend, increasing from an average of 6.3 cases per year in 2011-2013 to 29.3 cases per year in 2019-2021. This increase was predominantly driven by early-stage (I/II) tumors (75.9%), with the parotid gland being the most common primary site. Multivariable analysis identified age > 55 years and AJCC Stage IV disease as independent poor prognostic factors. Surgical intervention, including local tumor excision and glandectomy, was significantly associated with improved overall survival. Notably, patients who received a combination of surgery and radiotherapy had better outcomes compared to those who received either treatment alone.

conclusionThis large-scale study with extended follow-up clarifies the rising incidence and early-stage predominance of SGSC. Age, TNM stage, and surgical treatment were identified as key prognostic factors.

Indexed as

CarcinomaSalivary Gland NeoplasmsAdultAgedFemaleHumansIncidenceMaleMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesSEER ProgramSurvival RateIncidence trendsPrognosisSalivary glandsSecretory carcinomaThe SEER database

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.